New Challenges and Opportunities for AgNP: Virus
Many studies and applications are required within the legislation of each country, so that we can affirm that an agent has or does not act on a certain group of pathogens, be they viruses, fungi or bacteria. We cannot empower false researches (unspecified researches) for fear of not yet being sure or aware of the treatment of any disease.“researches” unspecified) for fear of not yet being sure or aware of the treatment of any disease.
Already exist in the literature studies that point to a promising advance the use of silver nanoparticles (AgNps) In multiple markets. Many successful attempts have been made in the study of the role of inhibition of AGNPS in virus growth, such as influenza virus, herpes simplex type 1 and type 2 (HSV-1 e HSV-2), vírus tacaribe Coxsackievirus B3 (TCRV), Vaccinia virus (VACV), human parainfluenza virus type 3 (HPIV-3), hepatitis B virus (HBV) And varicella (MPV). However, the exact mechanism for the action of these nanoparticles is still little known. But it is reported in the literature that the smaller the size of the largest AGNPS is the effectiveness of inhibition. Table 1 shows some applications of silver nanoparticles with potential application in combating viruses.
Table 1 - Potential applications of AgNp from virus checks
AgNps stabilized with mercaptoethanesulfonate, for example, inhibit HSV-1 infection because they help to prevent the virus from binding to host cells and thereby entering the virus into the cells. Another reason is that AgNps functionalized with mercaptoethanesulfonate have the ability to mimic heparan sulfate (primary HSV cellular receptor) and, therefore, these AgNps compete with the virus for binding in the cell.
The antimicrobial effectiveness of AgNps has been widely analyzed over the past decade, but the demonstration of its activity against viruses as a potential weapon is recent. In fact, AgNps can be active against a wide range of viruses, with the possibility that they are less likely to develop resistance compared to conventional antivirals. Nanoparticles have a strong antiviral potential and, due to their multiple interactions with glycoprotein receptors, they can inhibit viral multiplication within the host cell, preventing replication or blocking the entry of viral particles into the host cell.
It is known that viruses, such as obligate intracellular parasite infection has its amplified form through their placement with bacteria and other microorganisms. In this context, TNS has in its portfolio a unique range of products for antibacterial treatment, which help control and spread of viruses that use bacteria as hosts, increasing the range of propagation.
In conclusion, silver nanoparticles may have different properties as a result of its production method (size, shape, binding agent and level of dispersion), and further studies are warranted to elucidate its mechanism of action, which makes it possible to exploit this nanomaterial in the clinical setting against viral infections.
The TNS points out that there are few published studies on the use of silver nanoparticles in combating Covid-19.